ERBB2 and gastric cancer: To investigate whether upregulated SHCBP1 confers trastuzumab sensitivity, we examined SHCBP1 status by IHC in 22 HER2-positive gastric cancer patients who received trastuzumab-based therapy (Supplementary Table 2).